SEC Form 4 · accession 0001209191-15-070308
Q Therapeutics, Inc. · [NONE]
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Steven John Borst
Officer — Chief Executive Officer · Director
Period of report
Sep 9, 2015
Accepted (ET)
Sep 11, 2015 · 3:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001366541
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $0.70 | Sep 9, 2015 | A | 400,000 | A | Sep 8, 2016 | Sep 8, 2025 | Common Stock | 400,000 | 2,536,674 | D |
| Option to Purchase Common StockF2 | $0.70 | Sep 9, 2015 | A | 100,000 | A | — | Sep 8, 2025 | Common Stock | 100,000 | 2,636,674 | D |
| Option to Purchase Common StockF3 | $0.70 | Sep 9, 2015 | A | 100,000 | A | — | Sep 8, 2025 | Common Stock | 100,000 | 2,736,674 | D |
Explanation of responses
- F1Option shall vest at the rate of 28% on the one year anniversary of the grant date and 2% per month thereafter.
- F2Option will vest in full upon the closing of an equity and/or debt financing in the cumulative amount of $10 million on or prior to June 30, 2016.
- F3Option to vest in full upon the first patient dosed in the Company's Phase I clinical trial.